Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

DO2A

Product Specifications

UNSPSC Description

DO2Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. DO2A can be used for conjugation of peptides and radionuclides.

Target Antigen

Biochemical Assay Reagents

Type

Biochemical Assay Reagents

Related Pathways

Others

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/do2a.html

Solubility

10 mM in DMSO

Smiles

O=C(CN1CCNCCN(CCNCC1)CC(O)=O)O

Molecular Weight

288.34

Shipping Conditions

Room temperature

Product Datasheet

http://file.medchemexpress.com/batch_PDF/HY-W726767/DO2A-DataSheet-MedChemExpress.pdf

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-W726767/

Clinical Information

No Development Reported

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Adra2c Rat shRNA Plasmid (Locus ID 24175)
TR712849 1 Kit

Adra2c Rat shRNA Plasmid (Locus ID 24175)

Ask
View Details
Anti-IL12A/IL-12 p35/NKSF1 Antibody (R3H77)
RHD83901 100 μg

Anti-IL12A/IL-12 p35/NKSF1 Antibody (R3H77)

Ask
View Details
STK38 (Serine/Threonine Kinase 38, Ndr Ser/Thr Kinase-like Protein, OTTHUMP00000016293, Nuclear Dbf2-related 1, Serine Threonine Protein Kinase, NDR, NDR1) (AP)
MBS6134967-01 0.1 mL

STK38 (Serine/Threonine Kinase 38, Ndr Ser/Thr Kinase-like Protein, OTTHUMP00000016293, Nuclear Dbf2-related 1, Serine Threonine Protein Kinase, NDR, NDR1) (AP)

Ask
View Details
STK38 (Serine/Threonine Kinase 38, Ndr Ser/Thr Kinase-like Protein, OTTHUMP00000016293, Nuclear Dbf2-related 1, Serine Threonine Protein Kinase, NDR, NDR1) (AP)
MBS6134967-02 5x 0.1 mL

STK38 (Serine/Threonine Kinase 38, Ndr Ser/Thr Kinase-like Protein, OTTHUMP00000016293, Nuclear Dbf2-related 1, Serine Threonine Protein Kinase, NDR, NDR1) (AP)

Ask
View Details
SEMA3C (m)-PR
sc-44381-PR 10 µM, 20 µL

SEMA3C (m)-PR

Ask
View Details